Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma

Affiliations

• ¹ The John Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA. YZhang13@tuftsmedicalcenter.org.
• ² Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA. YZhang13@tuftsmedicalcenter.org.
• ³ Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
• ⁴ Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA.
• ⁵ The John Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA.
• ⁶ University of Texas Southwestern Medical Center, Dallas, TX, USA.